March 20, 2013 /PRNewswire/ --
- A fast and easy way to control the growth of digital content
- A scalable service based solution that can support a full pull marketing roll out
- A condensed version of the full Agnitio Rainmaker suite due to launch in June
A simple, intuitive and fast way to control the ever growing range of digital content being produced has been launched by Agnitio, the leaders in pull marketing for the pharmaceutical industry.
Rainmaker One is a service-based solution that can be tailored to the specific needs of pharmaceutical companies. Providing typical App features while removing the complexity of managing independent Apps, it also offers the scalability to support the implementation of a full pull marketing roll out to achieve multi-channel, rich data capture.
"With the benefits of content update and re-use functionality, Rainmaker One is a highly flexible way to manage, administer, publish and retire content," says
, Chief Operating Officer of Agnitio. "A traditional App approach tends to end with the production of a huge amount of unrelated content which can be both costly and extremely difficult to control.
"Rainmaker One ensures greater reuse of content across channels, simplifies the technical and IT resource around distribution, and makes sharing between agencies and customers easy. It also negates the need to have an internal App store and MDM to manage users and content."
Agnitio's new offering also empowers pharma marketeers, giving them the autonomy to internally review, approve, publish, update and retire content without involvement from IT or other departments.
Rainmaker One is an edited version of the new Agnitio Rainmaker software suite which is set to launch in June. An updated version of Agnitio's current offering, which has been developed over many years, the Rainmaker suite is easy to install and integrates with a range of existing systems, allowing for true individualisation of customer communications.
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts